{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:09:03Z","timestamp":1780412943016,"version":"3.54.1"},"reference-count":53,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["CAMP grant"],"award-info":[{"award-number":["CAMP grant"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stockholm County Council\/region Stockholm","award":["ALF grant"],"award-info":[{"award-number":["ALF grant"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020142","name":"Center for Medical Innovation","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100020142","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish Cancer Society","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"name":"Excellence of Science Projects","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G047417N"],"award-info":[{"award-number":["G047417N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G089515N"],"award-info":[{"award-number":["G089515N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003077","name":"Knowledge Foundation","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100003077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007229","name":"Bijzonder Onderzoeksfonds","doi-asserted-by":"publisher","award":["BOFEXP2017001002"],"award-info":[{"award-number":["BOFEXP2017001002"]}],"id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2022,7,29]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Chronic HBV\/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV\/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection in vivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A DNA prime-protein boost strategy was evaluated for immunogenicity in mice and rabbits. Its ability to circumvent T-cell tolerance was assessed in immunocompetent hepatitis B surface antigen (HBsAg)-transgenic mice. Neutralisation of HBV and HDV was evaluated both in vitro and in immunodeficient human-liver chimeric mice upon adoptive transfer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The prime-boost strategy elicits robust HBV\/HDV-specific T-cells and preS1-antibodies that can effectively prevent HBV and HDV (co-)infection in vitro and in vivo. In a mouse model representing the chronic HBsAg carrier state, active immunisation primes high levels of preS1-antibodies and HDAg-specific T-cells. Moreover, transfer of vaccine-induced antibodies completely protects HBV-infected human-liver chimeric mice from HDV superinfection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The herein described preS1-HDAg immunotherapy is shown to be immunogenic and vaccine-induced antibodies are highly effective at preventing HBV and HDV (super)infection both in vitro and in vivo. Our vaccine can complement current and future therapies for the control of chronic HBV and HDV infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2022-327216","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T13:20:34Z","timestamp":1660742434000},"page":"1186-1195","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections"],"prefix":"10.1136","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-6161","authenticated-orcid":false,"given":"Rani","family":"Burm","sequence":"first","affiliation":[{"name":"Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Maravelia","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf","family":"Ahlen","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[{"name":"Institute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"German Center for Infection Research, DZIF, External partner site, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Caro Perez","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pasetto","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Urban","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya","family":"Van Houtte","sequence":"additional","affiliation":[{"name":"Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Verhoye","sequence":"additional","affiliation":[{"name":"Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Johansson","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, \u00d6rebro University, Orebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Frelin","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8858-5132","authenticated-orcid":false,"given":"Matti","family":"S\u00e4llberg","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-234X","authenticated-orcid":false,"given":"Philip","family":"Meuleman","sequence":"additional","affiliation":[{"name":"Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"2025090711283724000_72.6.1186.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61931-9"},{"key":"2025090711283724000_72.6.1186.2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/141.5.590"},{"key":"2025090711283724000_72.6.1186.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.126"},{"key":"2025090711283724000_72.6.1186.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.013"},{"key":"2025090711283724000_72.6.1186.5","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"2025090711283724000_72.6.1186.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316601"},{"key":"2025090711283724000_72.6.1186.7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatitis D","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J Hepatol"},{"key":"2025090711283724000_72.6.1186.8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir Ther"},{"key":"2025090711283724000_72.6.1186.9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025090711283724000_72.6.1186.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"2025090711283724000_72.6.1186.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27102"},{"key":"2025090711283724000_72.6.1186.12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"2025090711283724000_72.6.1186.13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323888"},{"key":"2025090711283724000_72.6.1186.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.7.2208"},{"key":"2025090711283724000_72.6.1186.15","doi-asserted-by":"publisher","DOI":"10.1159\/000050042"},{"key":"2025090711283724000_72.6.1186.16","first-page":"181","article-title":"Modulation of hepatitis delta virus infection by vaccination with synthetic peptides: a preliminary study in the woodchuck model","volume":"382","author":"Bergmann","year":"1993","journal-title":"Prog Clin Biol Res"},{"key":"2025090711283724000_72.6.1186.17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840120508"},{"key":"2025090711283724000_72.6.1186.18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jmv.1890410308","article-title":"Partial control of hepatitis delta virus superinfection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus","volume":"41","author":"Karayiannis","year":"1993","journal-title":"J Med Virol"},{"key":"2025090711283724000_72.6.1186.19","first-page":"207","article-title":"Towards a vaccine for the prevention of hepatitis delta virus superinfection in HBV carriers","volume":"382","author":"Ponzetto","year":"1993","journal-title":"Prog Clin Biol Res"},{"key":"2025090711283724000_72.6.1186.20","first-page":"201","article-title":"The effects of using recombinant vaccinia viruses expressing either large or small HDAg to protect woodchuck hepadnavirus carriers from HDV superinfection","volume":"382","author":"Eckart","year":"1993","journal-title":"Prog Clin Biol Res"},{"key":"2025090711283724000_72.6.1186.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00245-6"},{"key":"2025090711283724000_72.6.1186.22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00645-13"},{"key":"2025090711283724000_72.6.1186.23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.24.12980-12985.2003"},{"key":"2025090711283724000_72.6.1186.24","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.8348"},{"key":"2025090711283724000_72.6.1186.25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309809"},{"key":"2025090711283724000_72.6.1186.26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B treatment: what we know now and what remains to be researched","volume":"3","author":"Suk-Fong Lok","year":"2019","journal-title":"Hepatol Commun"},{"key":"2025090711283724000_72.6.1186.27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","article-title":"Targeting innate and adaptive immune responses to cure chronic HBV infection","volume":"156","author":"Gehring","year":"2019","journal-title":"Gastroenterology"},{"key":"2025090711283724000_72.6.1186.28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301073"},{"key":"2025090711283724000_72.6.1186.29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.8.1269"},{"key":"2025090711283724000_72.6.1186.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104816","article-title":"Mechanisms of HBV immune evasion","volume":"179","author":"Kuipery","year":"2020","journal-title":"Antiviral Res"},{"key":"2025090711283724000_72.6.1186.31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2017.05.017","article-title":"Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro","volume":"509","author":"Rydell","year":"2017","journal-title":"Virology"},{"key":"2025090711283724000_72.6.1186.32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121960"},{"key":"2025090711283724000_72.6.1186.33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front Immunol"},{"key":"2025090711283724000_72.6.1186.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.018"},{"key":"2025090711283724000_72.6.1186.35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/infdis\/jiaa036","article-title":"Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections","volume":"223","author":"Maravelia","year":"2021","journal-title":"J Infect Dis"},{"key":"2025090711283724000_72.6.1186.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.04.059"},{"key":"2025090711283724000_72.6.1186.37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29239"},{"key":"2025090711283724000_72.6.1186.38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02528-09"},{"key":"2025090711283724000_72.6.1186.39","doi-asserted-by":"publisher","DOI":"10.1126\/science.3865369"},{"key":"2025090711283724000_72.6.1186.40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4741"},{"key":"2025090711283724000_72.6.1186.41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1715"},{"key":"2025090711283724000_72.6.1186.42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20657"},{"key":"2025090711283724000_72.6.1186.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)01388-3"},{"key":"2025090711283724000_72.6.1186.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.08.014"},{"key":"2025090711283724000_72.6.1186.45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025090711283724000_72.6.1186.46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28280"},{"key":"2025090711283724000_72.6.1186.47","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and peginterferon alfa-2a in adults with hepatitis B E antigen-positive Immune-Tolerant chronic hepatitis B virus infection","volume":"69","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"2025090711283724000_72.6.1186.48","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6700-1_1"},{"key":"2025090711283724000_72.6.1186.49","doi-asserted-by":"crossref","DOI":"10.3390\/v13081532","article-title":"Cell culture models for the study of hepatitis D virus entry and infection","volume":"13","author":"Heuschkel","year":"2021","journal-title":"Viruses"},{"key":"2025090711283724000_72.6.1186.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.016"},{"key":"2025090711283724000_72.6.1186.51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor Myrcludex B: effects on bile acid disposition and tenofovir pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025090711283724000_72.6.1186.52","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.chembiol.2018.04.011","article-title":"De novo macrocyclic peptide inhibitors of hepatitis B virus cellular entry","volume":"25","author":"Passioura","year":"2018","journal-title":"Cell Chem Biol"},{"key":"2025090711283724000_72.6.1186.53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin Exp Immunol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2022-327216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:28:51Z","timestamp":1757269731000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2022-327216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,5]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/gutjnl-2022-327216"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2022-327216","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}